Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Clinical trial NCT06948084 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06948084
- Sponsor
- National Cancer Institute (NCI)
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-26
- Primary completion
- 2028-02-28
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.